OPKO Health, Inc. (NASDAQ:OPK) Given Consensus Rating of “Hold” by Analysts

Shares of OPKO Health, Inc. (NASDAQ:OPK) have been assigned a consensus recommendation of “Hold” from the five analysts that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and one has assigned a buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $1.55.

A number of equities research analysts recently issued reports on OPK shares. Wall Street Zen upgraded shares of OPKO Health from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. HC Wainwright reaffirmed a “buy” rating on shares of OPKO Health in a research report on Wednesday, July 29th. Barrington Research cut OPKO Health from an “outperform” rating to a “market perform” rating in a research report on Wednesday, April 29th. Finally, Weiss Ratings upgraded OPKO Health from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, May 18th.

OPKO Health Stock Performance

OPK stock opened at $1.40 on Friday. The company has a quick ratio of 2.93, a current ratio of 3.35 and a debt-to-equity ratio of 0.28. The company has a market capitalization of $1.04 billion, a price-to-earnings ratio of -15.56 and a beta of 1.51. OPKO Health has a 12 month low of $0.98 and a 12 month high of $1.73. The firm has a 50 day moving average of $1.38 and a two-hundred day moving average of $1.27.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings results on Monday, July 27th. The biotechnology company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.07. The company had revenue of $163.58 million for the quarter, compared to analyst estimates of $131.23 million. OPKO Health had a negative net margin of 12.40% and a negative return on equity of 5.88%. OPKO Health’s quarterly revenue was up 4.3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.19) EPS. As a group, equities analysts anticipate that OPKO Health will post -0.24 EPS for the current fiscal year.

Institutional Investors Weigh In On OPKO Health

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. OP Asset Management Ltd acquired a new position in OPKO Health in the 1st quarter valued at $1,257,000. First Trust Advisors LP bought a new position in OPKO Health in the 1st quarter worth $570,000. UBS Group AG lifted its position in OPKO Health by 12.1% during the 4th quarter. UBS Group AG now owns 5,352,784 shares of the biotechnology company’s stock worth $6,745,000 after acquiring an additional 577,248 shares during the last quarter. Comerica Bank lifted its position in OPKO Health by 7.1% during the 4th quarter. Comerica Bank now owns 120,000 shares of the biotechnology company’s stock worth $151,000 after acquiring an additional 8,000 shares during the last quarter. Finally, State of Wyoming bought a new stake in OPKO Health during the first quarter valued at about $190,000. 64.63% of the stock is currently owned by institutional investors and hedge funds.

About OPKO Health

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.